Drug Insights

Unveiling Escitalopram: How to Search for it on Synapse

9 February 2024
2 min read

Escitalopram, marketed under the trade name Esertia, is an orally administered selective serotonin reuptake inhibitor. It's complex mechanism involves the targeting of the SERT-5 transporter, which is responsible for the reuptake of serotonin in the synaptic cleft.Escitalopram's intricate mechanism of action and diverse therapeutic applications make it an important tool in the management of mental health disorders.The development of Escitalopram was done by H. Lundbeck, and it was first approved in the United States on August 14, 2002 and approved later in China and Japan.Escitalopram occurs as a fine, white to slightly-yellow powder.Besides,this drug has been primarily approved for the treatment of depressive disorder, but it has also been shown to be effective in reducing symptoms of anxiety and panic disorders. Click on the image below to begin the exploration journey of Escitalopram through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

First Participant Dosed in RS Oncology's Phase 2 Trial of RSO-021 for Chest Tumor and Lung Metastases
Latest Hotspot
3 min read
First Participant Dosed in RS Oncology's Phase 2 Trial of RSO-021 for Chest Tumor and Lung Metastases
9 February 2024
RS Oncology Confirms Initial Participant Receives Dosage in Stage 2 Trial (MITOPE) Examining RSO-021 in Malignant Chest Tumor and Lung Metastases Therapy.
Read →
Expert Tips for Searching Ketamine on Synapse
Drug Insights
2 min read
Expert Tips for Searching Ketamine on Synapse
9 February 2024
Ketamine is a small molecule drug that acts as a modulator at the N-methyl-D-aspartate (NMDA) receptor.
Read →
Sirius Therapeutics Launches Phase One Study for Innovative Anticoagulant to Combat Thromboembolic Conditions
Latest Hotspot
3 min read
Sirius Therapeutics Launches Phase One Study for Innovative Anticoagulant to Combat Thromboembolic Conditions
9 February 2024
Sirius Therapeutics has initiated a first-stage clinical study for an advanced, extended-duration Factor XI siRNA anticoagulant, aimed at addressing thromboembolic conditions.
Read →
Navigating Health Information: How to Use Synapse to Search for Mirtazapine
Drug Insights
2 min read
Navigating Health Information: How to Use Synapse to Search for Mirtazapine
9 February 2024
Mirtazapine acts as an alpha-2 adrenergic receptor (ADRA2) antagonist, causing the release of norepinephrine and serotonin in the brain.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.